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Abstract 
Aim: In the present study, we aimed to assess serum concentrations of zinc (Zn), copper 
(Cu), iron (Fe), cadmium (Cd), lead (Pb), manganese (Mn), vitamins A (retinol), D (cho-
lecalciferol) and E (α-tocopherol) in patients with coronary artery disease (CAD) and to 
compare with healthy controls. 
Methods: A total of 30 CAD patients and 20 healthy subjects were included in this study. 
Atomic absorption spectrophotometry (UNICAM-929) was used to measure heavy metal 
and trace element concentrations. Serum α-tocopherol, retinol and cholecalciferol were 
measured simultaneously by high performance liquid chromatography (HPLC). 
Results: Demographic and baseline clinical characteristics were not statistically different 
between the groups. Serum concentrations  of retinol (0.3521±0.1319 vs. 0.4313±0.0465 
mmol/I, p=0.013), tocopherol (3.8630±1.3117 vs. 6.9124±1.0577 mmol/I, p<0.001), chole-
calciferol (0.0209±0.0089 vs. 0.0304±0.0059 mmol/I, p<0.001) and Fe (0.5664±0.2360 vs. 
1.0689±0,4452 µg/dI, p<0.001) were significantly lower in CAD patients. In addition, 
while  not  statistically  significant  serum  Cu  (1.0164±0.2672  vs.  1.1934±0.4164  µg/dI, 
p=0.073) concentrations were tended to be lower in patients with CAD, whereas serum 
lead (0.1449±0.0886 vs. 0.1019±0.0644 µg/dI, p=0.069) concentrations tended to be higher.  
Conclusions: Serum level of trace elements and vitamins may be changed in patients 
with CAD. In this relatively small study we found that serum levels of retinol, tocopher-
ol, cholecalciferol, iron and copper may be lower whereas serum lead concentrations may 
be increased in patients with CAD. 
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INTRODUCTION 
Coronary artery disease (CAD) is a leading cause 
of  morbidity  and  mortality  in  developed  countries 
and is emerging as an epidemic in developing coun-
tries (1). Traditional risk factors such as serum cho-
lesterol, blood pressure and smoking account for not 
more than 50% of CAD mortality (2). There is strong 
evidence that oxidative free radicals have a role in the 
development of degenerative diseases including CAD 
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(3). Oxidative free radicals increase the peroxidation 
of low density lipoprotein (LDL) thereby increasing 
its uptake by macrophages with increased foam cell 
formation  and  atherosclerosis,  though  other  mecha-
nisms  may  exist  (4).  Each  antioxidant  has  different 
and important mechanisms of action since oxidative 
damage  can  be  caused  by  lipid-  or  water-soluble 
molecules. Lipid-soluble antioxidants are likely to be 
very important in preventing the peroxidation of LDL 
and this action could be paramount in the prevention 
of atherosclerosis. As lypophilic molecules, vitamin E 
and beta-carotene are incorporated into the LDL par-
ticle.  Vitamin  E  plays  an  essential  protective  role 
against free radical damage (5). Previous experimental 
and epidemiologic evidence suggested that some an-
tioxidant vitamins appear to be important in reducing 
the risk of CAD (6). 
Studies on the roles of trace elements in health 
and disease over the past 50 years have led to a good 
understanding of their mode of action and why they 
are essential to life (7). Some studies have assessed the 
association between iron status and CAD risk but the 
results have been inconsistent (8,9). 
The aim of the present study was to investigate 
the changes occurring  in the serum  level zinc (Zn), 
copper  (Cu),  iron  (Fe),  cadmium  (Cd),  lead  (Pb), 
manganese (Mn), vitamins A (retinol), D (cholecalcif-
erol) and E (α-tocopherol) in patients with CAD.  
MATERIALS AND METHODS 
The study population included 30 patients hav-
ing angiographically demonstrated CAD and 20 pa-
tients having normal coronary arteries attending car-
diology clinic at Yuzuncu Yil University Hospital. The 
study  was  approved  by  the  local  ethics  committee 
according to the declaration of Helsinki, and patients 
gave written informed consent. 
Sample Collection And Analysis 
Blood samples were collected into tubes without 
coagulant. Serum was obtained by centrifugation at 
2500  rpm  for 15  minutes  and  stored  at  −80°C  until 
assayed. Serum α-tocopherol, retinol and cholecalcif-
erol were measured simultaneously by high perfor-
mance liquid chromatography (HPLC) (10-12). Serum 
concentrations  of  Zn,  Cu,  Fe,  Cd,  Pb  and  Mn  were 
determined by Atomic Adsorption Spectrophotome-
ter. 
Statistical Analysis 
Data  were  presented  as  mean±standard  devia-
tion (SD). Using SPSS package 16.0 (SPSS Inc. Chica-
go, IL, USA), data between the groups were compared 
with  Student’s  t  test  for  continuous  variables  and 
chi-square  t-test  for  continuous  variables. 
Mann-Whitney’s U-test was used for variables with-
out normal distribution. A two-tailed P-value of <0.05 
was considered significant. 
RESULTS AND DISCUSSION 
Clinical  characteristics  and  serum  cholesterol 
levels were not significantly different in patients with 
and without CAD (Table 1). Comparisons of the levels 
of the vitamins (retinol, tocopherol and cholecalcifer-
ol), and trace elements and heavy metals (Zn, Cu, Fe, 
Cd, Pb and Mn) in patients with CAD and the control 
group are shown in Table 2. Compared with the con-
trol group, serum concentrations of retinol, tocopher-
ol, cholecalciferol and iron were significantly lower in 
patients with CAD.  
 
Table 1: Clinical characteristics of study population. 
  Patients with CAD 
(n=30) 
Control group 
(n=20) 
P-value 
Age (years)  59.1±10.6  57.5±9.9  0.613 
BMI (kg/m2)  29.0396±4.0172  27.9001±3.5504  0.309 
Smoking (%)  19 (% 63.3)  11 (% 55)  0.383 
Hypertension (%)  19 (% 63.3)  7 (% 35.0)  0.082 
Diabetes mellitus (%)  13 (% 43.3)  5 (% 25.0)  0.237 
Total cholesterole (mg/dl)  184.5±40.2  203.7±37.8  0.120 
Triglyceride (mg/dl)  200.8±96.4  177.8±52.8  0.572 
LDL cholesterol (mg/dl)  120.5±20.8  133.0±28.6  0.178 
HDL cholesterol (mg/dl)  39.4±7.5  42.7±10.0  0.331 
Creatinine (mg/dl)  0.85±0.17  0.87±0.21  0.849 
BMI: body mass index, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein 
Data is presented as mean ±SD. 
 Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
458 
Table 2: Serum levels of vitamins and trace elements in study population. 
  Patients with CAD 
(n=30) 
Control group 
(n=20) 
P value 
Retinol (mmol/I)  0.3521±0.1319  0.4313±0.0465  0.013 
Tocopherol (mmol/I)  3.8630±1.3117  6.9124±1.0577  <0.001 
Cholecalciferol (mmol/I)  0.0209±0.0089  0.0304±0.0059  <0.001 
Fe (µg/dI)  0.5664±0.2360  1.0689±0,4452  <0.001 
Mn (µg/dI)  0.0606±0.0558  0.0429±0.0638  0.304 
Pb (µg/dI)  0.1449±0.0886  0.1019±0.0644  0.069 
Cu (µg/dI)  1.0164±0.2672  1.1934±0.4164  0.073 
Cd (µg/dI)  0.0070±0.0046  0.0087±0.0060  0.282 
Zn (µg/dI)  0.8514±0.5522  0.9087±0.1833  0.657 
Cd: cadmium , Cu: copper, Fe: iron, Mn:manganese, Pb: lead, Zn: zinc 
Data is presented as mean ±SD. 
 
 
In  this  study,  we  found  that  serum  concentra-
tions  of  retinol,  tocopherol,  cholecalciferol  and  Fe 
were significantly decreased in patients with CAD. In 
addition, while not statistically significant, serum Cu 
concentrations  tended  to  be  lower  in  patients  with 
CAD, whereas serum Fe concentrations tended to be 
higher.  
CAD has been associated with several risk fac-
tors  including  family  history,  age,  elevated  blood 
cholesterol, diabetes mellitus, cigarette smoking and 
hypertension (13).  Several  trace  elements  have  also 
been implicated in the pathogenesis of CAD (14). Low 
serum Zn levels have been associated with increased 
cardiovascular mortality (14). The results of the pre-
sent study show that serum Zn concentrations were 
significantly  lower  in  the  control  group.  Lower  Zn 
levels in CAD may be a cause or a result of another 
unknown parameter. Lukaski et al. (1988) observed a 
slight increase in serum Cu and a signficant increase 
in urine Cu levels in patients suffering from myocar-
dial infarction (MI) (15). Reunanen et al. (1996) found 
increased levels of serum Cu in patients with CAD 
(14). In contrast, in our study, the serum Cu concen-
trations tended to be lower in patients with CAD.  
Epidemiological  investigations  that  associate 
body  Fe  stores  with  CAD  risk  have  produced  con-
flicting results; these may in part be explained by the 
use of nonspesific measures of body Fe stores, such as 
serum  transferrin  (16-19).  The  strongest  supporting 
evidence that Fe is a risk factor for CAD stems from a 
cohort study of eastern Finnish men, in which high 
levels  of  serum  ferritin  and  dietary  Fe  intake  were 
positively associated with the incidence of myocardial 
infarction. Ascherio et al. (1994) reported an increased 
risk of nonfatal MI or fatal CAD with Fe intake (17). 
Sullivan et al. (1981) proposed that depletion of body 
Fe stores reduced the risk of CAD (16). Most subse-
quent  prospective  studies  investigating  whether  Fe 
status or dietary Fe intake is associated with an in-
creased risk of MI or CAD have not supported the 
hypothesis that high body Fe stores increase the risk 
of  CAD  (20,21,18).  Accordingly,  we  found  signifi-
cantly lower serum iron levels in patients with CAD.  
Because of its possible role in preventing heart 
disease researchers have taken interest in fat-soluble 
tocopherol.  Recent  studies  have  suggested  that 
α-tocopherol  supplementation  can  help  reduce  the 
incidence of coronary disease (1,22). However, a large 
prospective  study  found  no  benefit  of  tocopherol 
supplemantation  in  preventing  CAD.  Levels  of  to-
copherol were reported to be decreased in coronary 
artery disease (23).Our results also demonstrate that 
serum tocopherol levels were lower in CAD patients 
compared to controls. 
As far as we know, there is no study examining 
serum Cd levels in CAD in the literature. We have 
found  that  serum  Cd  levels  were  significantly  de-
creased  in  CAD.  Therefore,  the  significance  of  this 
finding should be further analysed in larger studies.  
Mn  is  an  element  essential  for  health  in  trace 
amounts, but toxic at higher levels. There are a few 
reports in the literature examining the effects of excess 
oral exposure of humans to Mn. The urine of CAD 
patients  also  shows  higher  Mn  concentrations  than 
that  of  healthy  controls  (24).  In  atherosclerotic  sub-
jects, the Mn content of the heart and aorta of athero-
sclerotic subjects is lower and plasma levels are higher 
than  in  healthy  controls (25-27).  This  increase  is  so 
rapid and specific that it may be used as a diagnostic 
indicator of a recent MI. In the present study however, 
Mn concentrations were not significantly increased in 
patients with CAD.  
Blood Pb level was not found to be associated 
with coronary heart disease incidence (28). The car-
diovascular effects of Pb have been associated with 
increased blood pressure and hypertension. Studies in Int. J. Med. Sci. 2011, 8 
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general populations have identified a positive associ-
ation  of  Pb  exposure  with  clinical  cardiovascular, 
CAD  and  stroke  mortality;  and  peripheral  arterial 
disease,  but  the  number  of  studies  is  small  (29,30). 
Numerous  experimental  studies  in  animals  have 
shown irrefutable evidence that chronic exposure to 
low  Pb  levels  results  in  arterial  hypertension  that 
persists long after the cessation of Pb exposure (29). 
We  couldn’t  found  information  about  Pb  levels 
among  patients  with  CAD  having  no  history  of  Pb 
exposure  in  literature.  In  the  present  study,  it  was 
found  that  mean  levels  of  serum  Pb  tended  to  be 
higher in CAD patients.  
We found that mean values for retinol were sig-
nificantly lower in patients with CAD compared to 
the control group. Other investigators have also re-
ported decreased retinol levels in patients with CAD 
(31,32). In other studies, Levels of retinol were similar 
in patients with CAD compared to controls (5,6,31,32). 
Numerous  studies  have  explored  whether  retinol 
supplements can help to prevent cardiovascular dis-
eases. Results of large randomized controlled trials of 
the impact of antioxidant vitamin supplements have 
been  ambiguous  or  contradictory  (33).  The  current 
evidence does not support indiscriminate use of reti-
nol to prevent or to reduce CAD (4,33).  
Similar to results reported in previous studies, 
we found serum cholecalciferol levels to be lower in 
CAD.  Cholecalciferol  deficiency  is  associated  with 
increased cardiovascular risk, above and beyond es-
tablished  cardiovascular  risk  factors (34,35).  Several 
mechanisms may explain the link between cholecal-
ciferol deficiency and cardiovascular disease. Clinical 
studies  have  reported  cross-sectional  associations 
between lower cholecalciferol levels and plasma renin 
activity, blood pressure, coronary artery calcification 
and prevalent cardiovascular disease (36-41). 
In conclusion, serum levels of trace elements and 
vitamins may be changed in patients with CAD. The 
higher or lower levels may be both a cause and effect 
of atherosclerosis or the result of another unknown 
parameter.  In  this  relatively  small  study  we  found 
that serum levels of retinol, tocopherol, cholecalcifer-
ol, Fe and Cu may be lower whereas serum Pb con-
centrations may be increased in patients with CAD. 
These  findings  need  to  be  further  investigated  in 
larger well designed studies. 
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